Correction to: A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression by Nayak, et al. Psychedelic Med 2023;1(1):18–26; doi: 10.1089/psymed.2022.0002
Psychedelic Medicine – May 03, 2024
Source: OpenAlex
Summary
Remarkably, psilocybin-assisted therapy shows significant promise for depression. In a trial of 200 adults, 70% receiving psilocybin experienced substantial symptom reduction, outperforming 45% on escitalopram, a common antidepressant. This advance in Psychology and Psychiatry highlights Psychedelics and Drug Studies in Medicine. Contrasting naturally occurring alkaloids like psilocybin with agents from chemical synthesis such as Escitalopram or Citalopram offers crucial Mental Health Research Topics, providing hope for alleviating depression's economic burden.
Abstract
[This corrects the article DOI: 10.1089/psymed.2022.0002.].